# **ED GUIDE TO** COVID-19

#### Nomenclature:

Virus: SARS-CoV-2 Infection: COVID-19

*Types*: 1. L Type (70%) – More aggressive 2. S Type (30%) – Less aggressive (Note: This is currently being disputed) \* Thought to originate from Bat or Pangolin

#### **Epidemiology:**

#### *Attack rate* = 30-40%

 $R_0 = 2.2 - 3.1$  (SARS 2-5, MERS 0.3-0.8, Measles 12-18, Ebola 1.5 - 2.5

COVID-19

*Case fatality Rate* = 1 - 2% (For medically attended patients) *Incubation time* = 3 - 14 days (mean 5.1; outliers 19 - 27davs)

Disease Severity: 80% mild; 15% severe (hypoxic/hospitalized); 5% Critical (ICU/Ventilated) Age: 0-14 (1%);15-49 (55%);50-64 (28%);>65 (15%).

### **Transmission:**

Droplet and fomites. Airborne plausible; NOT confirmed. ? oral-fecal. 12 - 23% of transmission asymptomatic or presymptomatic. Infectious period up to 10-14 d. NO evidence of re-infection after recovery.

### HCW risk of Infection:

China (3.5 – 7%); Italy (20%).

#### **Disease Course:**

Stage 1 (Viral Response Phase) – Viral incubation and replication. Mild Symptoms (fever, cough, malaise) Stage 2 (Pulmonary Phase) – Adaptive immune response. Hypoxia/Dyspnea. Abnormal labs/CXR. Admission. Stage 3 (Hyperinflammation Phase) - Disregulated cytokine storm. ARDS, DIC, multiorgan failure, Shock. Day 1 – Fever, cough Day 6-7 – Dyspnea Dav 9-10 - Sepsis Day 10-12 - ARDS Day 16 – Death


Day 26 – Recovery/discharge (severe disease)

**Risk Factors for Increased Case Fatality Rate:** Age > 60, Male, HTN, DM2, CKD, CVD, CAD, COPD, Cancer immunocompromised (Smoker small **†** risk)

Calleer, minunocomptomised. (billoker small   115k).										
70-	80+									
79										
12.8	20.2									
8.0	14.8									
	79 12.8									

#### Resources:

Emcrit, RebelEM, Onepageicu.com, References on request.



Severe vs Non-Severe (%): Fever (88/81), cough (71/66), fatigue (60/44), dyspnea (44/6), sputum production (38/28), SOB (36/13), myalgias (26/13), Chills (26/11), dizzy (16/12), headache (11/13), sore throat (8/10), N/V (6/6), diarrhea (6/6), rhinorrhea (3/5).

Up to 57% of patients have NO fever at triage. **RR** can often be normal due to maintenance of lung compliance. Consider walk challenge to identify exertional hypoxia. Other symptoms include altered mentation, hemoptysis, anorexia, anosmia, aguesia.

**Imaging:** 



 $\overline{CXR}$  – Hazy, bilateral, peripheral opacities (rare unilateral)

CT – Peripheral ground glass opacities

US – B-lines, pleural thickening, consolidations.

Labs:

Labs	WBC	PMN	LMN	Plt	CRP	LDH	Trop
Results	N/↓	ſ	↓	¥	î	1	↑
Labs	СК	Creat	Fibr	Ferr	Alb	AST/ALT	D-d
Results	1	1	V	1	Ļ	1	1

Affects T cells. Usually & Lymphocytes (83%). Can have normal WBC. Neutrophil:lymphocyte ratio > 3 predicts severe illness. CRP/Ferr ↑ with severity. Troponin ↑ starting day 4(? myocardial injury). \CRP/LDH/D-d predictor of severity/death. DIC =(D-d/INR,  $\downarrow$ Fibr).

# **Diagnosis:**

RT-PCR - Sensitivity ~ 75%. (Single negative test does NOT rule out COVID-19). Sensitivity 97% if combined with CT Chest.

### Treatment:

Early identification of severe disease. Mainly supportive. 02 - Pulse ox targets: Resp disease 88-92% (92-95% if drop below 85% on exertion). No disease 93 - 96%. If >4L  $O_2$  consider ICU. If >6L  $O_2$  consider intubation. *Fluids* – Conservative fluid strategy. RL > NS.

Antibiotics - If septic (Ceftriaxone+Azithromycin). Avoid Vanco to J AKI risk. Consider Linezolid if MRSA risk. Pressors - Norepi (1<sup>st</sup>-line). Target MAP 60-65. Add Vasopressin - refractory. Add Dobutamine - cardiac shock. CPR:

Defibrillation - Droplet only. CPR - Airborne PPE, secure airway then start CPR.

### Intubation:

Negative pressure room. Airborne PPE. Most experienced intubator. Airway team ≤ 3 in room. Passive preoxygenation. Use VL. Viral filter. RSI. Ketamine (1mg/kg) or Etomidate (0.3mg/kg; avoid in septic shock). Rocuronium (1.5mg/kg). Early pressors (norepi). Push dose pressors ready (phenyl).

## PPE:

AGMPinED (Intubation, NIPPV, BVM, CPR, nebs, open suction,  $? > 6L O_2 NC)$  - Airborne precautions (N95/PAPR). Virus airborne for up to 60 min post intubation. Direct patient care - Droplet precautions. Includes defib. Vent Settings: ARDSnet.org (just in case)

Lung compliance maintained but atelectasis and drowning of alveoli. ARDS =  $PaO_2/FIO_2 < 300$ . ARDS ventilation – AC control (paralyzed)/support (spont.). RR=continue baseline minute ventilation (RRmax <35). IFR 60-80L/min. Vt 4-8ml/kg (start 6ml/kg). I:E ratio (I duration ≤ E duration). Pplat  $\leq$  30cmH<sub>2</sub>O. High PEEP. SPO<sub>2</sub> goal 88-96%. Consider permissive hypercapnea (pH  $\sim$  7.15)

FiO2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1.0	
PEEP	5-14	14-16	16-20	20	20	20-22	22	24	
Disposition:									

1. *Mild* – Consider d/c: mild symptoms. Normal labs/CXR.  $O_2 > 93\%$ . Consider swab if risk factors. Self isolate. Other considerations: age, ADLs/supports, 3rd trimester, HCW. 2. Moderate - Consider admission: Signs of COVID19 + hypoxic (at rest or exertion). RF for **†** CFR. Abnormal CXR (bilat patchy)/labs (\LMN; N/Lratio, dd, crp, ldh, trop). 3. Severe – Consult ICU – refractory hypoxemia (4L  $O_2$  > = 93%), resp acidosis (pH<7.2), clinical resp failure, hypotension (SBP<90). Consider intubation if  $6L O_2 =$ <93%. Watch for myocardial injury/VT/VF. Consider appropriate care based on age, frailty scale, cognitive function, comorbidities, severity of disease, goals of care.

# **Pediatric Considerations:**

Mild or asymptomatic (6% severe). <5y/o most vulnerable. M > F. AVOID intubation (use HFNC/Bipap). Consider  $2^{\circ}$ PNA. MDI for asthma. Adult size teen = Adult Treatment. Unknown low risk (?ACE2 receptor maturity vs immunity).

## **Return to work (BC CDC):**

10 days from onset of symptoms (and asymptomatic).

# **Common Ouestions:**

NSAIDS - Are SAFE but Acetaminophen first line anitpyretic. ACEi/ARBs - Continue use even if COVID-19 +. Chloroquine/Hvdroxvchloroquine - NOT recommended (vet). Steroids – NOT recommended (may have role in refractory shock)

unless medically necessary (asthma/copd). IVIG - MAY have role in severe cases.

Safety of HFNC - Controversial. Likely has a role but need negative pressure room. Use supported by SSC/ANZICS/WHO. Vertical Transmission - NO evidence.